CJC-1295 (No DAC)

CJC-1295 (No DAC) – Research-Grade Growth Hormone–Releasing Factor Analog (GRF 1–29)

CJC-1295 (No DAC), also referred to as Modified GRF (1–29), is a synthetic peptide analog of the endogenous human growth hormone–releasing factor fragment comprising amino acid residues 1–29. This compound incorporates targeted amino acid substitutions designed to enhance enzymatic stability while retaining the core structural features of native GRF. In laboratory research environments, CJC-1295 (No DAC) is utilized to study growth hormone–releasing factor signaling dynamics, receptor interaction models, and peptide stability characteristics independent of long-acting carrier complexes.

Unlike CJC-1295 variants that incorporate a Drug Affinity Complex (DAC), the No DAC form does not covalently bind to serum proteins in vitro. This distinction allows researchers to examine GRF-mediated receptor activation and downstream signaling pathways without extended systemic persistence or albumin-binding effects. Its defined sequence and absence of carrier modification support controlled use in mechanistic assays, receptor-specific investigations, and comparative studies involving native GRF and other growth hormone–releasing peptides under controlled laboratory conditions.